Duopharma Biotech Berhad Statistics
Total Valuation
Duopharma Biotech Berhad has a market cap or net worth of MYR 1.14 billion. The enterprise value is 1.45 billion.
Market Cap | 1.14B |
Enterprise Value | 1.45B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
Earnings Date | Nov 8, 2024 |
Ex-Dividend Date | Aug 29, 2024 |
Share Statistics
Duopharma Biotech Berhad has 961.94 million shares outstanding. The number of shares has increased by 0.74% in one year.
Shares Outstanding | 961.94M |
Shares Change (YoY) | +0.74% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.31% |
Owned by Institutions (%) | 21.58% |
Float | 454.59M |
Valuation Ratios
The trailing PE ratio is 23.16 and the forward PE ratio is 14.51. Duopharma Biotech Berhad's PEG ratio is 0.78.
PE Ratio | 23.16 |
Forward PE | 14.51 |
PS Ratio | 1.53 |
PB Ratio | 1.65 |
P/FCF Ratio | 43.39 |
PEG Ratio | 0.78 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.78, with an EV/FCF ratio of 54.93.
EV / Earnings | 29.31 |
EV / Sales | 1.94 |
EV / EBITDA | 11.78 |
EV / EBIT | 18.01 |
EV / FCF | 54.93 |
Financial Position
The company has a current ratio of 4.35, with a Debt / Equity ratio of 75.74.
Current Ratio | 4.35 |
Quick Ratio | 2.93 |
Debt / Equity | 75.74 |
Debt / EBITDA | 4.27 |
Debt / FCF | 19.92 |
Interest Coverage | 3.31 |
Financial Efficiency
Return on equity (ROE) is 7.23% and return on invested capital (ROIC) is 4.32%.
Return on Equity (ROE) | 7.23% |
Return on Assets (ROA) | 3.88% |
Return on Capital (ROIC) | 4.32% |
Revenue Per Employee | 453,350 |
Profits Per Employee | 29,963 |
Employee Count | 1,650 |
Asset Turnover | 0.58 |
Inventory Turnover | 1.99 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.43% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +4.43% |
50-Day Moving Average | 1.21 |
200-Day Moving Average | 1.23 |
Relative Strength Index (RSI) | 41.04 |
Average Volume (20 Days) | 663,120 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Duopharma Biotech Berhad had revenue of MYR 748.03 million and earned 49.44 million in profits. Earnings per share was 0.05.
Revenue | 748.03M |
Gross Profit | 269.13M |
Operating Income | 80.48M |
Pretax Income | 60.52M |
Net Income | 49.44M |
EBITDA | 119.57M |
EBIT | 80.48M |
Earnings Per Share (EPS) | 0.05 |
Balance Sheet
The company has 221.16 million in cash and 525.57 million in debt, giving a net cash position of -304.41 million or -0.32 per share.
Cash & Cash Equivalents | 221.16M |
Total Debt | 525.57M |
Net Cash | -304.41M |
Net Cash Per Share | -0.32 |
Equity (Book Value) | 693.95M |
Book Value Per Share | 0.72 |
Working Capital | 536.93M |
Cash Flow
In the last 12 months, operating cash flow was 52.53 million and capital expenditures -26.15 million, giving a free cash flow of 26.38 million.
Operating Cash Flow | 52.53M |
Capital Expenditures | -26.15M |
Free Cash Flow | 26.38M |
FCF Per Share | 0.03 |
Margins
Gross margin is 35.98%, with operating and profit margins of 10.76% and 6.61%.
Gross Margin | 35.98% |
Operating Margin | 10.76% |
Pretax Margin | 8.09% |
Profit Margin | 6.61% |
EBITDA Margin | 15.98% |
EBIT Margin | 10.76% |
FCF Margin | 3.53% |
Dividends & Yields
This stock pays an annual dividend of 0.03, which amounts to a dividend yield of 2.37%.
Dividend Per Share | 0.03 |
Dividend Yield | 2.37% |
Dividend Growth (YoY) | 21.74% |
Years of Dividend Growth | n/a |
Payout Ratio | 44.75% |
Buyback Yield | -0.74% |
Shareholder Yield | 1.63% |
Earnings Yield | 4.32% |
FCF Yield | 2.30% |
Stock Splits
The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.
Last Split Date | Sep 6, 2021 |
Split Type | Forward |
Split Ratio | 1.3333333333 |